Sunovion announces Health Canada approval of Kynmobi (apomorphine hydrochloride) soluble film for the treatment of Parkinson's disease OFF episodes

Sunovion Pharmaceuticals

15 June 2020 - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes.

Sunovion Pharmaceuticals announced today that Health Canada has approved Kynmobi (apomorphine hydrochloride) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterised, in part, by tremor, stiffness, slowed movement or other symptoms. These disruptive episodes can occur any time throughout the day and get worse as the disease progresses. 

Kynmobi was previously approved by the U.S. FDA on 21 May 2020.

Read Sunovion Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada